共 23 条
- [22] Brigatinib dose rationale in anaplastic lymphoma kinase-positive non-small cell lung cancer: Exposure-response analyses of pivotal ALTA study (vol 9, pg 718, 2020) CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2021, 10 (09): : 1119 - 1122